CURRENT TREATMENT PATTERNS AND SURVIVAL IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINDINGS FROM A BRIEF SURVEY OF EUROPEAN PHYSICIANS

被引：0
|
作者：
Davis, K. L. [1 ]
Lin, H. M. [2 ]
Zhang, S. [3 ]
Kaye, J. A. [4 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Takeda Pharmaceut Int Inc, Deerfield, IL USA
[4] RTI Hlth Solut, Waltham, MA USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.1284
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN186
引用
收藏
页码：A1221 / A1221
页数：1
相关论文
共 50 条
  • [21] Lenalidomide for the treatment of relapsed or refractory multiple myeloma
    Weber, D. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 22 - 24
  • [22] Elotuzumab in the treatment of relapsed and refractory multiple myeloma
    Grosicki, Sebastian
    Bednarczyk, Martyna
    Barchnicka, Agnieszka
    Grosicka, Olga
    FUTURE ONCOLOGY, 2021, 17 (13) : 1581 - 1591
  • [23] Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
    Bumma, Naresh
    Richter, Joshua
    Jagannath, Sundar
    Lee, Hans C.
    Hoffman, James E.
    Suvannasankha, Attaya
    Zonder, Jeffrey A.
    Shah, Mansi R.
    Lentzsch, Suzanne
    Baz, Rachid
    Maly, Joseph J.
    Namburi, Swathi
    Pianko, Matthew J.
    Ye, Jing Christine
    Wu, Ka Lung
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Byun, Ja Min
    Martinez-Lopez, Joaquin
    Cassady, Kaniel
    Deveaux, Michelle
    Chokshi, Dhruti
    Boyapati, Anita
    Hazra, Anasuya
    Yancopoulos, George D.
    Sirulnik, L. Andres
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Houvras, Yariv
    Dhodapkar, Madhav V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (22)
  • [24] Pomalidomide for the treatment of relapsed and refractory multiple myeloma
    Guidetti, Anna
    Prada, Claudia Paba
    Laubach, Jacob P.
    Varga, Cindy
    Maglio, Michelle E.
    McKenney, Mary
    Doss, Deborah
    Schlossman, Robert L.
    Mitsiades, Constantine
    Hideshima, Teru
    Gorgun, Gullu T.
    Ghobrial, Irene M.
    Raje, Noopur
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1089 - 1108
  • [25] Thalidomide for the treatment of relapsed and refractory multiple myeloma
    Cool, RM
    Herrington, JD
    PHARMACOTHERAPY, 2002, 22 (08): : 1019 - 1028
  • [26] Isatuximab for the treatment of relapsed/refractory multiple myeloma
    Richardson, Paul G.
    Beksac, Meral
    Spicka, Ivan
    Mikhael, Joseph
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (12) : 1395 - 1403
  • [27] Treatment options for relapsed and refractory multiple myeloma
    Nooka, Ajay K.
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    Lonial, Sagar
    BLOOD, 2015, 125 (20) : 3085 - 3099
  • [28] TREATMENT PATTERNS OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN EUROPE (EU-28)
    Gatopoulou, X.
    Bardenheuer, K.
    Van Hoorenbeeck, S.
    Kempel, A.
    VALUE IN HEALTH, 2016, 19 (07) : A715 - A716
  • [29] Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
    Huang, Jeffrey Shang-Yi
    Wang, Ming-Chung
    Yeh, Su-Peng
    Chen, Tsai-Yun
    Teng, Chieh-Lin Jerry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S188 - S189
  • [30] TREATMENT SEQUENCING PATTERNS AND COSTS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Potluri, R.
    Farr, A. M.
    Hirji, I
    Davis, C.
    Bhandari, H.
    Oukessou, A.
    VALUE IN HEALTH, 2015, 18 (07) : A450 - A450
12345